Reducing the risk of venous thromboembolism using apixaban – patient perspectives and considerations. Should more attention be given to females?

BACKGROUND: New oral anticoagulant agents, such as apixaban, rivaroxaban, dabigatran, or endoxaban, have recently become for patients an alternative option to conventional treatment in the therapy of venous thromboembolism (VTE). Thus, we aimed to review the available information on adverse events (...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabbian, Fabio, De Giorgi, Alfredo, Tiseo, Ruana, Zucchi, Beatrice, Manfredini, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734816/
https://www.ncbi.nlm.nih.gov/pubmed/26869771
http://dx.doi.org/10.2147/PPA.S82484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734816/
https://www.ncbi.nlm.nih.gov/pubmed/26869771
http://dx.doi.org/10.2147/PPA.S82484

Ejemplares similares